The effects of long-term administration of recombinant bovine somatotropin (Posilac) and Synovex on performance, plasma hormone and amino acid concentration, and muscle and subcutaneous fat fatty acid composition in Holstein-Friesian bull calves.

The effect of recombinant somatotropin (rbST), Synovex (Syn), and their combination (rbST+Syn) on intact male calves was examined in an experiment that lasted an average of 238 d. Holstein-Friesian bull calves were allotted to one of four subtreatments (n = 14/treatment) in a factorial arrangement. There were two levels of rbST (0; rbST) and two levels of the estrogenic growth promoter Synovex (0; Syn). The rbST was administered once every 2 wk as injections of 500 mg of Posilac. Synovex (C and S) was implanted at 90-d intervals. The animals were fed for ad libitum consumption a diet with a metabolizable energy concentration of 11.7 MJ/kg DM and 15% crude protein. The hot carcasses were weighed after the removal of kidney, pelvic, and cod fats, which were weighed separately. The 12th rib cut was saved for analysis. Average daily gain and feed conversion efficiency were increased by rbST treatment by 9% (P < .005) and 10% (P < .016), respectively. There was no significant effect of Syn treatment, nor was there a rbST x Syn interaction. The proportion of the fat of the large depots in the carcass was reduced by 34% (P < .0001) and in the longissimus muscle by 32% (P < .16) owing to the rbST treatment. The plasma concentrations of GH, insulin, and thyroxin were increased by rbST treatment (P < .001, P < .01, and P < .03, respectively). The concentration of IGF-I was not affected. Synovex had no effect on plasma hormone concentration. Plasma essential and nonessential amino acid concentrations were reduced by 14 and 9%, respectively, when rbST was injected. Concentrations of cholesterol and fatty acids in muscle and subcutaneous fat were not affected (P > .072) by the rbST treatment. Synovex increased the monounsaturated fatty acids (MUFA), and the combinaton of Syn with rbST reduced polyunsaturated fatty acid (PUFA) concentration in the longissimus muscle (at the 12th rib). The reduced muscle fat content of the rbST-treated animals was associated with a trend toward an increase in polyunsaturated fatty acids.

A method for the determination of glucose synthesis in isolated bovine hepatocytes.

A simple method for determining glucose synthesis from radiolabeled precursors in isolated bovine hepatocytes using ion exchange resins is presented. This method allows processing of multiple small volume samples using suspensions of anion and cation exchange resins rather than traditional stacked column separation methods. Hepatocytes were isolated from calf liver by collagenase perfusion of the caudate lobe and were incubated with (14)C-labeled lactate or propionate as gluconeogenic substrates. Glucose synthesis was determined in an aliquot of cell suspension that was vortexed with a slurry of anion exchange (acetate form) resin, followed by a slurry of cation exchange resin. Newly synthesized, labeled glucose was recovered in the supernatant after centrifugation and quantitated by scintillation counting. Using this procedure, more than 98% of the unused labeled precursor was bound to the ion exchange resin and essentially 100% of a labeled glucose tracer was recovered in the supernatant. Pretreatment of hepatocyte suspensions with glucose oxidase was shown to eliminate the accumulation of radioactivity in the supernatant, thus confirming the specificity of this technique for measurement of newly synthesized glucose. This method was sensitive to changes in the rate of hepatic gluconeogenesis that resulted from changes in substrate concentration or the addition of glucagon or fatty acids to the hepatocyte incubations.

Effect of somatotropin and feed restriction on body composition and adipose metabolism in obese Zucker rats.

The objective of the present study was to determine whether exogenous somatotropin (STH) administration in conjunction with feed restriction could alter the composition of gain in the obese rat. Five-week-old female lean and obese Zucker rats were assigned to the following treatments for 6 wk: ad libitum fed (AL), restricted (approximately 75% of AL lean), and restricted with STH (2 mg STH/day). Growth rate was decreased in restricted groups and was normalized to that of the AL lean group in restricted rats treated with STH. In lean rats, restriction decreased protein accretion. Restriction plus STH treatment decreased lipid accretion but increased protein accretion and body weight gain compared with the AL lean group. As expected, feed restriction reduced body size in obese rats, but carcass lipid was maintained at 44%, a level similar to that of the AL obese rats. Lipid accretion rate was decreased with restriction in obese rats and was further reduced, to a level similar to that of the lean group, in the obese rats that were restricted and treated with STH. Protein accretion was decreased in the restricted obese group but was normalized in those treated with STH to a level similar to that in the AL lean group. Basal rates of lipolysis in isolated adipocytes were not affected by STH. However, STH treatment normalized the responsiveness of cells from the obese rats to stimulation of lipolysis by isoproterenol. The results demonstrate that a combination of caloric restriction and STH was effective in normalizing body weight and composition of gain in the obese Zucker rat.

Comparison of daily versus continuous administration of somatotropin on growth rate, feed intake, and body composition in intact female rats.

The response to continuous delivery or daily bolus injection of porcine somatotropin (pST) was compared in mature, pituitary-intact female rats (225 g). Growth rate in control rats was approximately 1 g/d over the 14-d study. There was a dose-dependent (0, .4, 1.2, and 3.6 mg of pST/d; P < .001) increase in rate of gain with an interaction (P < .001) of dose and mode of delivery. The slope of the dose-response curve for growth rate was linear on a logarithmic scale for both modes of delivery but was greater for continuous delivery. At the low dose (.4 mg/d) pST stimulated gain (21.7 g/14 d above control, P < .05) when administered by daily injection but failed to stimulate gain (6.0 g/14 d above control, NS) when delivered continuously. At the high dose (3.6 mg/d), gain (above that in control rats) was 49.1 and 79.7 g/14 d for daily and continuous delivery; the two modes were different (P < .05) from each other. Feed intake and liver weights were also stimulated by pST in a dose-dependent manner. The increase in liver size was accompanied by a dose-dependent increase in liver DNA, indicative of an increase in cell number. Increased carcass gain was largely accounted for by increased carcass protein accretion. Rates of carcass lipid accretion were lower than those for protein accretion and were further decreased by pST, particularly by the high dose administered by continuous delivery, where a negative lipid accretion value was observed. Circulating IGF-I was increased by pST (P < .001) but was not affected by the mode of delivery. The results demonstrate that the increased gain observed in mature rats is largely due to lean tissue accretion and is accompanied by an increase in feed intake.

Comparative effectiveness of somatotropin and anabolic steroids in feedlot steers.

Crossbred steers (n = 252, BW = 379 +/- 28 kg) were allotted to 42 pens in a 2 x 3 factorial arrangement of treatments: control or steroid implant (STR; estradiol benzoate+progesterone [three lighter blocks reimplanted on d 84] and trenbolone acetate [reimplanted on d 63]), and either 0, 80, or 160 mg/wk of recombinant bovine somatotropin (bST). Steers were adapted to the finishing diet (12% roughage equivalent, 13% CP) before the start of the experiment and fed for 84 or 119 d. Blood samples were taken on d 0, 14, 28, 56, and 84 for plasma urea N (PUN), serum somatotropin (ST), plasma insulin-like growth factor I (IGF-I), and plasma amino acid assay. Few interactions were noted (P > .1). Gain was increased by both treatments: 1.30 vs 1.66 kg/d for control vs. STR (P < .001) and 1.44, 1.49, and 1.51 kg/d (linear, P = .07) for 0, 80, and 160 mg of bST/wk, respectively. Gain efficiency was also improved: 169 vs 205 g/kg (P < .001) and 177, 189, and 195 g/kg (linear, P < .001), respectively. Average PUN was decreased (P < .001) 29% by STR and decreased 17 and 29% by 80 and 160 mg of bST/wk, respectively (linear, P < .001). Somatotropin decreased mean serum ST compared with controls; STR increased ST 36% compared with controls. Average plasma IGF-I was increased (P < .001) 12% by STR and 13 and 19% (linear, P < .001) by 80 and 160 mg of bST/wk, respectively. Both STR and bST influenced (P < .05) plasma amino acid profiles. Indicators of carcass fatness were decreased linearly (P < .05) by bST; STR implant tended to decrease carcass fatness and increase longissimus muscle area, which was related to carcass weight. The anabolic effects of STR and bST were found to be additive and possibly independent in feedlot steers.

Performance, clinical chemistry, and carcass responses of finishing lambs to formulated sometribove (methionyl bovine somatotropin).

Formulated zinc methionyl bST (sometribove, 50, 100, or 150 mg) was administered as a single treatment once every 2 wk or as two equal treatments once/week to evaluate the efficacy of prolonged release delivery of bovine somatotropin (bST) in finishing lambs. Feed conversion during the 6-wk treatment period was improved 9 and 19% in lambs that received treatments once and twice/2 wk, respectively (P < .05), and the responses to differing doses were similar within a dosing frequency (P > .05). Carcass muscle:fat ratio indicators generally were affected in a dose-related manner and were independent of frequency of administration. For example, fat thickness was 17, 30, and 42% lower than control in lambs that received 50, 100, and 150 mg of formulated sometribove/2 wk, respectively (P < .05). Percentages of muscle were higher and of fat were lower with increasing dose of formulated sometribove, but weight of only fat was significantly affected (P < .05). Clinical chemistry indices of metabolic effects of bST (e.g., circulating bST, IGF-I, insulin, glucose, and urinary nitrogen concentrations) were affected in directions similar to those observed with bST administered by daily injection. The results of this study demonstrate the growth performance and carcass composition advantages of a formulation designed to deliver bST over a 2-wk period.

Effects of recombinant bovine somatotropin implants on serum concentrations of somatotropin, insulin-like growth factor-I and blood urea nitrogen in steers.

Four cross-bred beef steers averaging 346 kg were used in a 4 x 4 Latin square design to determine the effect of prolonged-release recombinant bovine somatotropin (rbGH) implants on serum concentrations of somatotropin (GH), insulin-like growth factor-I (IGF-I) and blood urea nitrogen (BUN). Recombinant bGH implants of 0, 40, 80 or 160 mg were administered subcutaneously in the tailhead during the 4 trial periods. Each steer received each treatment starting at 06:00 on day 0 with 21 days between treatments. Jugular vein blood samples were collected on days 0, 1, 2 and 3 (4 day time course for GH, IGF-I and BUN) and every 15 min (GH profile) for 6 h on day 3. Serum baseline GH values were higher (P < 0.10) for the 80 and 160 mg treatments than for the control, and peak amplitude was decreased (P < 0.05) by the 40 and 160 mg treatments. There was a trend (P < 0.11) for fewer GH peaks during the 160 mg treatment. Somatotropin concentrations decreased from day 1 to day 3 (P < 0.05) in a linear manner. Serum IGF-I concentrations increased (P < 0.05) in a linear dose-dependent manner from the 0 mg to the 160 mg treatment. BUN concentrations were not significantly altered by rbGH treatment. Results from this experiment indicate that rbGH implants significantly increase serum IGF-I and GH baseline concentrations while suppressing GH peak amplitude in finishing steers.

Effects of porcine somatotropin on growth and carcass composition of Meishan and Yorkshire barrows.

Effects of porcine somatotropin (pST) on growth and carcass characteristics of Meishan (Ms) and Yorkshire (Y) barrows given 3 mg of pST or saline daily were determined for two end points. First, 26 Ms and 26 Y barrows were treated from 119 d of age until the Y barrows reached 108 kg. Second, another 18 Ms barrows were treated to 108 kg BW. Age- and weight-matched treatments were analyzed. Results for both groups indicated pST effects (P < .05) for feed conversion (+) and intake (-), dressing percentage (-), percentage of carcass fat (-) and protein and water (+), leaf fat (-), backfat (BF) thickness (-), longissimus muscle area (LMA; +), skin thickness (+), muscle firmness and marbling scores (-), organ weights (+), belly (-), clear plate (-), ham (+), and total boneless cuts (BC; +). Somatotropin effects were also present for loin (-) and boneless Boston butt (BBB; +) in the age-matched group and for ADG (+), carcass weight (-), loin (-), jowl (-), and tenderloin (+) in the weight-matched group. Breed effects (P < .05), in favor of Y barrows, in both treatments existed for ADG (+) and feed intake (+), carcass weight (+), dressing percentage (+), LMA (+), skin thickness (-), muscle color and firmness scores (-), muscling score (+), all wholesale cuts (WC; +) except clear plate (age-matched), all trimmed cuts (TC; +) except picnic shoulder (weight-matched), and all BC (+). Breed effects, in favor of Y barrows, were also determined for carcass length (+), percentage of carcass ash (-), leaf fat (+), average BF thickness (+), and heart (-) and liver (-) weights in age-matched animals and percentage of carcass fat (-), protein (+), water (+), leaf fat (-), 10th rib, average, and P2 BF thicknesses (-), marbling score (-), femur length (-), and liver weights (+) in weight-matched animals. A higher response to pST (P < .05) was determined in Ms barrows than in Y barrows for percentage of carcass protein (+), liver (+), and heart (+) in the age-matched treatment and 10th rib BF thickness (-) and heart weight (+) in the weight-matched treatment. Yorkshire barrows treated with pST had more improved values for color score (+; age-matched) and BBB (+; weight-matched).

Performance, clinical chemistry, and carcass responses of finishing lambs to recombinant bovine somatotropin and bovine placental lactogen.

Bovine placental lactogen (PL) is a partial somatotropin agonist in the cow and decreases urea nitrogen, indicating increased nitrogen retention. In the present study, the somatogenic effects of bovine PL (bPL; 4 and 8 mg/d) were compared with those of bovine somatotropin (bST; 4 and 8 mg/d) in finishing lambs. Measures of comparison included growth performance, carcass composition, and growth-related clinical chemistry traits. Although feed efficiency during the first 3 wk of treatment with bPL was improved by 14% (P < .05), feed efficiency for the full 6-wk treatment period did not differ from that of control lambs. Responsiveness to bPL may have been attenuated by high titer antibodies present after 2 wk of treatment. However, bPL also did not influence growth-related clinical chemistry traits during short-term (7 d) treatment, strongly suggesting that bPL was ineffective in finishing lambs at the doses tested. In contrast, bST improved 6-wk feed efficiency by an average of 17% (P < .05) and decreased feed intake by an average of 12% (P < .05). In addition, measures of carcass composition including longissimus muscle area, specific gravity of the rack, kidney and pelvic fat, and fat thickness demonstrated that bST, but not bPL, treatment decreased carcass fatness and increased carcass leanness. Treatment with bST, but not with bPL, affected IGF-I, insulin, glucose, and urea nitrogen in a dose-related manner. Thus, daily injections of bPL did not affect either performance or carcass quality, whereas performance and carcass responses of finishing lambs to bST were consistent with those reported by others.

Comparison of performance, clinical chemistry, and carcass characteristics of finishing lambs treated with recombinant ovine or bovine somatotropins.

The variation in growth and carcass composition responses of lambs to somatotropin (ST) treatment may depend on the source of ST used as well as on other experimental conditions. In the present experiment, growth, carcass composition, and clinical chemistry responses to recombinantly produced ovine ST (oST) and two bovine ST (N-methionyl-bST[M-bST] and N-alanyl-bST[A-bST] were compared. Lambs weighing 42 kg were assigned to treatment groups of control (no injection) or 4 mg/d of M-bST, A-bST, or oST administered by s.c. injection for 6 wk. Growth rate was increased by an average of 30% and feed efficiency was improved by an average of 22% by ST treatment compared with control, and responses did not differ among ST. The IGF-I, insulin, and glucose concentrations were increased by 107, 700, and 53% compared with control, respectively, and did not differ among ST treatment groups. Urea nitrogen responses to A-bST and oST were transiently greater than those to M-bST. Although quality grade was not affected by treatment, an average .8-kg increase in weight of retail cuts was calculated from yield grade. Carcasses of ST-treated lambs were calculated to have 1.3 kg more muscle and 1.9 kg less fat. Although fat and muscle were affected more by oST than by M-bST on a percentage basis, they did not differ among treatment groups on a total weight basis. Thus, both bST variants and oST improved growth performance and carcass leanness. Decreased responses of some carcass variables to M-bST treatment may have been related to the presence of antibodies that were indicated by an increased number of positive responders in a relative bST binding assay.

Evaluation of long-term somatotropin implants in finishing pigs.

Ninety pigs were used to investigate the efficacy of long-term implants of porcine somatotropin (pST) in improving growth, feed:gain ratio, and carcass characteristics in pigs at three dose levels (0-, 100-, and 200-mg pST implant) from 71 to 99 kg live weight. The use of long-term implants did not alter (P > .05) growth rate. Administration of the 200-mg pST implant resulted in a 15% reduction in feed consumption, and this reduction was significant (P < .05). The feed:gain ratio was improved (P < .05) in pigs that received the 200- compared with 0-mg pST implant (3.2 vs 2.62 of kg feed/kg of gain). In pigs that received the 200- or 100-mg pST implant, there was a reduction (P < .05) in carcass weight; however, carcass length was similar (P > .05) regardless of pST treatment. Administration of the 200-mg pST implant resulted in 25 and 38% reductions (P < .05) in last rib fat and leaf fat compared with the 0-mg pST implant. The weights of kidneys and head were increased by the pST administration. The weights of wholesale cuts were not affected by the administration of the pST implant. However, separable skin and fat from the ham, loin, and picnic were lower (P < .05) in pigs that received the 200-mg pST than in pigs that received the 0-mg pST implant. Meat color and structure were similar across pST treatments, indicating that the use of long-term pST implants was not detrimental to meat quality.(ABSTRACT TRUNCATED AT 250 WORDS)

Comparison of the growth-promoting properties of daily versus continuous administration of somatotropin in female rats with intact pituitaries.

The effect of dose and mode of delivery of recombinant bovine (rbST) or porcine somatotropin (rpST) on the growth rate of female rats with intact pituitaries was investigated in a series of experiments. The overall objective of these studies was to compare the relationship of dose and mode of delivery on the growth response to somatotropin. The equivalence of rbST and rpST in stimulation of growth was demonstrated. In an initial study, treatment of rats with 0, .67 (3 mg/kg), or 2.0 mg/d (9 mg/kg) of rbST for 28 d resulted in ADG of .8, 2.6, and 3.8 g/d (P < .0001, SEM .1 g). A log-linear dose response to rbST in the range of .07 to 32 mg/d (.3 to 145 mg/kg) for the stimulation of gain was observed. Continuous delivery of rpST in bicarbonate buffer was achieved using osmotic pumps. Sustained, log-linear growth for doses of 0, .5, 1, 2, and 4 mg of rpST/d for 28 d was demonstrated. In a direct comparison of bolus injection and continuous delivery at doses of 0, .22, .67, 2.0, and 6.0 mg of rpST/d, a significant difference in slope (P < .0001) of the modes of delivery was observed; continuous delivery had a greater slope. Depending on the dose administered, bolus injection was either more (< .67 mg/d) or less efficacious (> .67 mg/d) than continuous delivery in its ability to stimulate growth in female rats with intact pituitaries. It is hypothesized that the difference in the slope of the dose-response curves can be accounted for by the animal's ability to utilize the hormone effectively.

Relationship of mode of porcine somatotropin administration and dietary fat to the growth performance and carcass characteristics of finishing pigs.

Ninety-six pigs were used to investigate the relationship of diet (control vs fat-supplemented with equal energy:protein ratios), porcine somatotropin (pST) administration (non-treated; 2 mg/d, daily injection; and 2 mg/d, 6-wk implant), and sex (barrows and gilts) to performance and carcass characteristics. Diet and pST treatments were initiated at 87 kg of BW and continued for 38 d. Both the fat-supplemented diet (P less than .001) and pST treatment (P less than .0001) improved feed efficiency. The effects of diet were accounted for by differences in energy density of the diets. Across diets, pST improved gain:feed ratio by 29 and 16% in pigs treated by daily injection and the implant, respectively; the two modes of delivery resulted in different responses (P less than .01). Circulating insulin-like growth factor I (IGF-I) levels, determined from blood samples drawn on d 35, were increased 2.5-fold above those of controls in pigs treated by either daily injection or the implant. However, the elevation of glucose and decrease in blood urea nitrogen concentrations in response to pST were of a greater magnitude in pigs treated by daily injection. Similarly, reductions in backfat thickness and the rate of backfat accretion determined by ultrasound were greater in response to the daily injection of pST than in response to the implant. Lean meat ratio, calculated from measurements with a Fat-O-Meater probe, was increased by 6 and 13% by the implant and daily injection, respectively. It is concluded that although the use of an implant that delivers pST on a continuous basis was as effective as the same dose administered as a bolus injection for increasing IGF-I levels, it was less effective in improving feed efficiency and carcass quality.

Dose-response effects of recombinant bovine somatotropin implants on feedlot performance in steers.

One hundred twenty crossbred beef steers averaging 377 kg were used in a 2 x 4 factorial experiment to determine the dose-response effects of recombinant bovine somatotropin (rbST) implants on growth performance and carcass characteristics. The implant dosages were 0 (sham), 40, 80, or 160 mg/wk administered s.c. in the tailhead region on a weekly basis throughout the experiment. The steers were fed a high-concentrate diet, which contained either a degradable (DP; soybean meal) or an escape (EP; corn gluten and blood meal) protein source. No dietary protein effect or dietary protein x rbST level interactions were detected. Recombinant bST decreased both DMI (P less than .10) and feed/gain (P less than .05) in a linear dose-dependent manner. Dosage of rbST did not significantly affect (P greater than .10) ADG or final weight of the steers. Recombinant bST decreased backfat depth (P less than .10), marbling score (P less than .05), and quality grade (P less than .10) and increased yield grade (P less than .10) in a linear dose-dependent manner. Soft tissue composition of the 9-10-11th rib section was altered (P less than .01) by rbST administration in a linear dose-dependent manner. The percentage of protein in the rib section was increased by 9.4% and fat was decreased by 11.8% at the 160 mg/wk rbST level compared with the sham-implanted steers. Recombinant bST did not affect (P greater than .10) dressing percentage, hot carcass weight, kidney, pelvic, and heart fat, or longissimus muscle area.(ABSTRACT TRUNCATED AT 250 WORDS)

The performance and carcass composition responses of finishing swine to a range of porcine somatotropin doses in a 1-week delivery system.

Four experiments using 580 barrows and 580 gilts (Study 1) and seven experiments using 500 barrows and 500 gilts (Study 2) were conducted at various geographical locations in the United States to determine the dose response of a pelleted form of porcine somatotropin (pST) relative to ADG, feed/gain (F/G), and percentage of carcass protein. Average initial weights for Studies 1 and 2 were 67.6 and 72.6 kg, respectively, and four pigs/pen were slaughtered when they achieved weights of 106.5 to 111.0 kg. In Study 1, pigs were implanted subcutaneously with pelleted pST doses of 0, 12, 24, 36, or 48 mg/wk and self-fed a corn-soybean meal diet containing 13.75% CP. Study 2 included two control groups self-fed a diet containing either 13.75 or 17% CP with added lysine. The pST-treated pigs were administered 12, 24, or 36 mg/wk, and all were offered the 17% CP diet. The pST treatments in Study 1 resulted in a linear reduction (P less than .05) in average daily feed intake (ADFI) and a quadratic (P less than .05) improvement in F/G and percentage of carcass protein. The pST treatments in Study 2 resulted in a linear reduction in ADFI (P less than .05), a linear improvement in F/G, and a quadratic increase in the percentage of carcass protein (P less than .05). Average daily gain was not affected in either study with this form of pST. The greatest increase in efficiency of lean gain was observed with the 36-mg dose for both Study 1 (9.4%) and Study 2 (10.8%). In Study 1, the force required to shear cores of the longissimus muscle was increased linearly with pST treatment (P less than .05). There was a similar linear increase in Study 2 with pST treatment (P less than .05); however, there was also an effect of sex (P less than .05) on shear force (gilts greater than barrows) that was similar in magnitude to that observed for pST treatment. Differences in sensory evaluation because of pST were minor and of the same magnitude as those observed between barrows and gilts. It was therefore concluded that weekly administration of pST improved F/G and percentage of carcass protein with no detrimental effects on palatability of cooked lean pork.

Finishing lamb performance responses to bovine and porcine somatotropins administered by Alzet pumps.

Daily injection of ovine and bovine somatotropin (oST and bST, respectively) has been shown to improve performance and carcass quality of finishing lambs. To evaluate responses to continuously released bST and porcine ST (pST), which have 99 and 91% sequence homology with oST, respectively, finishing lambs were implanted with 2-wk Alzet pumps containing bST or pST, which was released at rates of 2 or 4 mg/d. Six-week growth rate and feed efficiency responses to bST were greater than those to pST (P less than .05). Overall feed efficiency was improved 15% and growth rate was increased 16% in lambs treated with 4 mg/d of bST compared with control lambs and neither trait was affected in pST-treated lambs. Performance responses were reflected by changes in circulating glucose, blood urea nitrogen, and insulin-like growth factor I (IGF-I) concentrations. Scatchard analysis of sera with relative binding of greater than 30% revealed that average binding capacities and affinities of pST-treated lambs were 7.0 mg/liter and 6.0 x 10(9) liters/mol, respectively, and of bST-treated lambs were .8 mg/liter and 1.3 x 10(9) liters/mol, respectively. In addition, lambs with high-capacity pST antibodies had lower 6-wk IGF-I concentrations than those of controls, suggesting that these antibodies may have been attenuating responsiveness to pST. It is concluded that continuously released bST, but not pST, improves performance of finishing lambs.

Level of satiety: in vitro energy metabolism in brain during hypophagic and hyperphagic body weight recovery.

Rates of in vitro glucose and fatty acid oxidation were examined in four brain sites during hypophagic and hyperphagic recovery of normal body weight. Rats were fed 40, 100, or 160% of normal intake, via gastric intubation, for 3 wk. Another group of rats was starved until body weight loss was equivalent to weight loss in 40%-fed rats. Groups of rats were killed at the conclusion of tube feeding or fasting and at specific periods during recovery of body weight. Brain sites examined were the ventrolateral hypothalamus (VLH), ventromedial hypothalamus (VMH), a caudal brain stem site encompassing the area postrema-nucleus of the solitary tract (AP-NTS), and cortex. During recovery, rats previously fed 160% of normal intake (anorectic) maintained low rates of VLH fatty acid oxidation and were hypophagic until most excess fat was depleted. Conversely, rats previously fed 40% of normal intake (hungry) maintained high rates of VLH fatty acid oxidation and were hyperphagic until most deficient fat was repleted. Rats previously starved maintained high rates of VLH fatty acid oxidation during hyperphagic recovery, although levels of VLH fatty acid oxidation and food intake were initially low on refeeding. Rates of glucose oxidation in the brain sites examined did not relate well to energy balance status and the needed adjustments in food intake. The results indicated that the level of glucose oxidation in the VLH and AP-NTS responded to the level of energy immediately coming into the system (food intake).(ABSTRACT TRUNCATED AT 250 WORDS)

Purification and characterization of pituitary bovine somatotropin.

Bovine somatotropin (bST) has been isolated from pituitary glands and compared in a variety of chemical analyses and bioassays with somatotropin derived from recombinant Escherichia coli. Comparison of pituitary extracts and purified bST by Western blot analysis of two-dimensional gels suggested that the immunoreactive somatotropin species present in the extract were also present in the purified material, with no significant losses or degradation as a result of the purification method. NH2-terminal sequence analysis indicated the presence of equal quantities of Ala-Phe-Pro-Ala-Met-Ser-Leu-Ser- and Phe-Pro-Ala-Met-Ser-Leu-Ser- sequences. The Met-Ser-Leu-Ser-NH2-terminal sequence, a degradation product observed in NIH standard lots, was not detected. Assay of bioactivity in a bovine liver receptor-binding assay and in a female rat growth assay showed pituitary bST and recombinant methionyl-bovine somatotropin to be equipotent. Tryptic maps and sequence analysis of pituitary-derived somatotropin suggest the presence of isoaspartate derivatization at Asp128.

Site of action of putative lipostatic factor: hypothalamic metabolism of parabiotic rats.

Studies were conducted to determine whether metabolic adaptation occurred in the hypothalamus of overfed parabiotic rats and their partners to distinguish between the adaptations caused by increased caloric intake and those caused by the production of a "lipostatic factor." The induction of overfed obesity in one parabiotic partner was employed to test the hypothesis that a putative lipostatic factor produced in the obese parabiotic elicited the hypophagic-lipid-mobilizing effect observed in the lean parabiotic via alterations in hypothalamic fatty acid and glucose metabolism. Fatty acid oxidation in the ventrolateral hypothalamus (VLH) of overfed parabiotic rats and their partners was lower than in ad libitum parabiotic rats. Net flux of glucose through the VLH gamma-aminobutyric acid (GABA) shunt was elevated in overfed parabiotic rats compared with the net flux observed in their partners and ad libitum parabiotic rats, the levels being similar in these last two groups. Net flux of glucose through the ventromedial hypothalamic (VMH) pentose shunt in overfed parabiotic rats and their partners was elevated relative to ad libitum parabiotic rats. The putative lipostatic factor may act to regulate energy balance through modification of VLH fatty acid oxidation and/or glucose flux via the VMH pentose shunt.

Dynamics of recovery of body composition after overfeeding, food restriction or starvation of mature female rats.

In this study we examined the body composition of rats recovering from overfeeding, underfeeding or starvation. Female rats (220 g) were fed 160%, 100% or 40% of control intake, by stomach tube, until the 40% rats had lost 50 g. Other rats were starved to lose 50 g. Carcass composition was measured on one group from each treatment. The remaining rats returned to ad libitum feeding. The 160% rats were hypophagic and lost weight. Starved and 40% rats were hyperphagic and gained weight. Serum insulin increased with increased food intake. T4 was depressed by food restriction. T3 and T4 increased during weight loss in 160% rats. Carcass composition of rats from each treatment was determined at progressive stages of recovery. Overfed rats had gained 7 g of protein and 43 g of fat. Protein was soon lost but fat was still significantly increased after 44 d of recovery. Starved and restricted rats had lost 11 g of protein and 28 g of fat. Starved rats regained protein earlier than body fat. Restricted rats recovered body fat much earlier than body protein or weight. Body protein and fat may have individual regulatory mechanisms that work together to control body weight.